Home › Research › Treatments
The Indiana University Brain Health Program to deliver amyloid-targeted therapy to Alzheimer's disease patients
Brosch JR, Wang S, Apostolova LG, Agarwal A, Allen JW, Gutmann L, Tobar M, Gonzalez L et al.. Alzheimer's & dementia (New York, N. Y.), 2026-07-08
Topic: Amyloid, tau and blood-test diagnosis
Introduction The Indiana University Brain Health Program was developed to support safe implementation of amyloid-targeting therapies (ATTs) for early Alzheimer's disease (AD). Methods We established Neurology Brain Health Navigators (neuroBHNs) to extend our Brain Health Navigator model into specialty care. NeuroBHNs pre-screen patients for ATT eligibility, coordinate biomarker and imaging evaluation, provide structured education, and guide treatment initiation and monitoring. The program includes a dedicated social worker and insurance pre-authorization specialist to streamline infusion access. Blood pressure is monitored at each visit, and infusions are deferred if readings exceed 140/90 mmHg. Results Through December 16, 2025, 243 patients initiated lecanemab therapy. Apolipoprotein E (APOE) ε4 homozygotes were not excluded; 74% of treated patients carried at least one Apoε4 allele. The ARIA rate was 13.2%, and 40% of patients experienced infusion-related reactions. Conclusions A navigator-centered model can efficiently deliver ATT while supporting structured education, screening, and safety monitoring, potentially contributing to favorable safety outcomes.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Brosch, JR., Wang, S., Apostolova, L. G., Agarwal, A., Allen, J. W., Gutmann, L., et al. (2026). The Indiana University Brain Health Program to deliver amyloid-targeted therapy to Alzheimer's disease patients. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.70291
Vancouver
Brosch JR, Wang S, Apostolova LG, Agarwal A, Allen JW, Gutmann L, et al. The Indiana University Brain Health Program to deliver amyloid-targeted therapy to Alzheimer's disease patients. Alzheimer's & dementia (New York, N. Y.). 2026. doi:10.1002/trc2.70291. PMID: 42421820.
BibTeX
@article{brosch2026-42421820,
author = {Brosch, JR. and Wang, S. and Apostolova, L. G. and Agarwal, A. and Allen, J. W. and Gutmann, L. and Tobar, M. and Gonzalez, L. and others},
title = {{The Indiana University Brain Health Program to deliver amyloid-targeted therapy to Alzheimer's disease patients}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2026},
doi = {10.1002/trc2.70291},
pmid = {42421820},
url = {https://doi.org/10.1002/trc2.70291}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Through December 16, 2025, 243 patients initiated lecanemab therapy.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants243
- Effect size13.2%
- Evidence strengthLow
How this study scored 62/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 36 of the 58 points we could judge it on, which is 62 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 243 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42421820) |
| Free to read | 2 / 2 | Free to read |
| Points | 36 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 36 of the 58 points we could judge it on is 62 out of 100. |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “brain-health”
5 studies in the library carry the topic tag “brain-health”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.